Neuropsychiatric systemic lupus erythematosus (2nd part). Diagnostic and treatment tools in psychiatric or central nervous system manifestations in systemic lupus erythematosus;Neurolupus (2 e partie). Description des outils diagnostiques et thérapeutiques devant une manifestation psychiatrique ou neurologique centrale au cours du lupus érythémateux systémique

Revue de Medecine Interne

Volumn 33, Issue 9, 2012, Pages 503-513

  Lefevre G ^a   Zephir H ^a   Michelin, E ^a   Semah, F ^a   Warembourg, F ^a   Pruvo, J P ^a   Hachulla, E ^a   Lenfant, P ^a   Dubucquoi, S ^a   Vermersch, P ^a   Hatron, P Y ^a   Prin, L ^a   Launay, D ^a  

^a UNIV LILLE   (France)

Author keywords

Antiphospholipids; Neuropsychiatric systemic lupus erythematosus; Systemic lupus erythematosus

Indexed keywords

CLINICAL FEATURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NEUROPSYCHIATRY; OUTCOME ASSESSMENT; SHORT SURVEY; SYSTEMIC LUPUS ERYTHEMATOSUS; ALGORITHM; BRAIN VASCULITIS; CENTRAL NERVOUS SYSTEM; INCIDENCE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; REVIEW;

ALGORITHMS; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC TECHNIQUES, NEUROLOGICAL; HUMANS; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; NEUROPSYCHOLOGICAL TESTS;

EID: 84868303343     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/j.revmed.2012.03.354     Document Type: Short Survey

References (82)

1. er partie): description et démarche diagnostique et thérapeutique des manifestations neurologiques centrales et psychiatriques au cours du lupus érythémateux systémique. Rev Med Interne 2012, in press. 10.1016/j.revmed.2012.03.356.
2. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
3. Unterman A., Nolte J.E., Boaz M., Abady M., Shoenfeld Y., Zandman-Goddard G. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011, 41:1-11.
4. Ainiala H., Hietaharju A., Loukkola J., Peltola J., Korpela M., Metsanoja R., et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum 2001, 45:419-423.
5. Bertsias G.K., Ioannidis J.P., Aringer M., Bollen E., Bombardieri S., Bruce I.N., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010, 69:2074-2082.
6. Cotton F., Bouffard-Vercelli J., Hermier M., Tebib J., Vital Durand D., Tran Minh V.A., et al. MRI of central nervous system in a series of 58 systemic lupus erythematosus (SLE) patients with or without overt neuropsychiatric manifestations. Rev Med Interne 2004, 25:8-15.
7. Abreu M.R., Jakosky A., Folgerini M., Brenol J.C., Xavier R.M., Kapczinsky F. Neuropsychiatric systemic lupus erythematosus: correlation of brain MR imaging, CT, and SPECT. Clin Imaging 2005, 29:215-221.
8. Jennings J.E., Sundgren P.C., Attwood J., McCune J., Maly P. Value of MRI of the brain in patients with systemic lupus erythematosus and neurologic disturbance. Neuroradiology 2004, 46:15-21.
9. Katsumata Y., Harigai M., Kawaguchi Y., Fukasawa C., Soejima M., Kanno T., et al. Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus: a prospective cohort study. BMC Musculoskelet Disord 2010, 23:11-13.
10. Kozora E., Arciniegas D.B., Filley C.M., Ellison M.C., West S.G., Brown M.S., et al. Cognition, MRS neurometabolites, and MRI volumetrics in non-neuropsychiatric systemic lupus erythematosus: preliminary data. Cogn Behav Neurol 2005, 18:159-162.
11. Sabbadini M.G., Manfredi A.A., Bozzolo E., Ferrario L., Rugarli C., Scorza R., et al. Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus 1999, 8:11-19.
12. Sanna G., Piga M., Terryberry J.W., Peltz M.T., Giagheddu S., Satta L., et al. Central nervous system involvement in systemic lupus erythematosus: cerebral imaging and serological profile in patients with and without overt neuropsychiatric manifestations. Lupus 2000, 9:573-583.
13. Chinn R.J., Wilkinson I.D., Hall-Craggs M.A., Paley M.N., Shortall E., Carter S., et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997, 40:36-46.
14. Luyendijk J., Steens S.C., Ouwendijk W.J., Steup-Beekman G.M., Bollen E.L., van der Grond J., et al. Neuropsychiatric systemic lupus erythematosus: lessons learned from magnetic resonance imaging. Arthritis Rheum 2010, 63:722-732.
15. Petri M., Naqibuddin M., Carson K.A., Wallace D.J., Weisman M.H., Holliday S.L., et al. Brain magnetic resonance imaging in newly diagnosed systemic lupus erythematosus. J Rheumatol 2008, 35:2348-2354.
16. Appenzeller S., Rondina J.M., Li L.M., Costallat L.T., Cendes F. Cerebral and corpus callosum atrophy in systemic lupus erythematosus. Arthritis Rheum 2005, 52:2783-2789.
17. Cauli A., Montaldo C., Peltz M.T., Nurchis P., Sanna G., Garau P., et al. Abnormalities of magnetic resonance imaging of the central nervous system in patients with systemic lupus erythematosus correlate with disease severity. Clin Rheumatol 1994, 13:615-618.
18. West S.G., Emlen W., Wener M.H., Kotzin B.L. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995, 99:153-163.
19. Appenzeller S., Carnevalle A.D., Li L.M., Costallat L.T., Cendes F. Hippocampal atrophy in systemic lupus erythematosus. Ann Rheum Dis 2006, 65:1585-1589.
20. Appenzeller S., Pike G.B., Clarke A.E. Magnetic resonance imaging in the evaluation of central nervous system manifestations in systemic lupus erythematosus. Clin Rev Allergy Immunol 2008, 34:361-366.
21. Ainiala H., Dastidar P., Loukkola J., Lehtimaki T., Korpela M., Peltola J., et al. Cerebral MRI abnormalities and their association with neuropsychiatric manifestations in SLE: a population-based study. Scand J Rheumatol 2005, 34:376-382.
22. Appenzeller S., Li L.M., Costallat L.T., Cendes F. Neurometabolic changes in normal white matter may predict appearance of hyperintense lesions in systemic lupus erythematosus. Lupus 2007, 16:963-971.
23. Sibbitt W.L., Sibbitt R.R., Griffey R.H., Eckel C., Bankhurst A.D. Magnetic resonance and computed tomographic imaging in the evaluation of acute neuropsychiatric disease in systemic lupus erythematosus. Ann Rheum Dis 1989, 48:1014-1022.
24. Appenzeller S., Bonilha L., Rio P.A., Min Li L., Costallat L.T., Cendes F. Longitudinal analysis of gray and white matter loss in patients with systemic lupus erythematosus. Neuroimage 2007, 34:694-701.
25. Appenzeller S., Li L.M., Costallat L.T., Cendes F. Evidence of reversible axonal dysfunction in systemic lupus erythematosus: a proton MRS study. Brain 2005, 128:2933-2940.
26. Hachulla E., Michon-Pasturel U., Leys D., Pruvo J.P., Queyrel V., Masy E., et al. Cerebral magnetic resonance imaging in patients with or without antiphospholipid antibodies. Lupus 1998, 7:124-131.
27. Jung R.E., Segall J.M., Grazioplene R.G., Qualls C., Sibbitt W.L., Roldan C.A. Cortical thickness and subcortical gray matter reductions in neuropsychiatric systemic lupus erythematosus. PLoS One 2010, 5:e9302.
28. Sibbitt W.L., Sibbitt R.R., Brooks W.M. Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999, 42:2026-2038.
29. Castellino G., Govoni M., Giacuzzo S., Trotta F. Optimizing clinical monitoring of central nervous system involvement in SLE. Autoimmun Rev 2008, 7:297-304.
30. Castellino G., Padovan M., Bortoluzzi A., Borrelli M., Feggi L., Caniatti M.L., et al. Single photon emission computed tomography and magnetic resonance imaging evaluation in SLE patients with and without neuropsychiatric involvement. Rheumatology (Oxford) 2008, 47:319-323.
31. Sibbitt W.L., Brooks W.M., Haseler L.J., Griffey R.H., Frank L.M., Hart B.L., et al. Spin-spin relaxation of brain tissues in systemic lupus erythematosus. A method for increasing the sensitivity of magnetic resonance imaging for neuropsychiatric lupus. Arthritis Rheum 1995, 38:810-818.
32. Miller D.H., Buchanan N., Barker G., Morrissey S.P., Kendall B.E., Rudge P., et al. Gadolinium-enhanced magnetic resonance imaging of the central nervous system in systemic lupus erythematosus. J Neurol 1992, 239:460-464.
33. Lawn N.D., Westmoreland B.F., Kiely M.J., Lennon V.A., Vernino S. Clinical, magnetic resonance imaging, and electroencephalographic findings in paraneoplastic limbic encephalitis. Mayo Clin Proc 2003, 78:1363-1368.
34. Reske D., Petereit H.F., Heiss W.D. Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system - value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 2005, 112:207-213.
35. Joseph F.G., Lammie G.A., Scolding N.J. CNS lupus: a study of 41 patients. Neurology 2007, 69:644-654.
36. Calabrese L.H., Molloy E.S., Huang D., Ransohoff R.M. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease. Arthritis Rheum 2007, 56:2116-2128.
37. Lefevre G., Queyrel V., Maurage C.A., Laurent C., Launay D., Lacour A., et al. Effective immune restoration after immunosuppressant discontinuation in a lupus patient presenting progressive multifocal leukoencephalopathy. J Neurol Sci 2009, 287:246-249.
38. Warnatz K., Peter H.H., Schumacher M., Wiese L., Prasse A., Petschner F., et al. Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature. Ann Rheum Dis 2003, 62:50-57.
39. Brooks W.M., Jung R.E., Ford C.C., Greinel E.J., Sibbitt W.L. Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus. J Rheumatol 1999, 26:81-85.
40. Axford J.S., Howe F.A., Heron C., Griffiths J.R. Sensitivity of quantitative (1)H magnetic resonance spectroscopy of the brain in detecting early neuronal damage in systemic lupus erythematosus. Ann Rheum Dis 2001, 60:106-111.
41. Sundgren P.C., Jennings J., Attwood J.T., Nan B., Gebarski S., McCune W.J., et al. MRI and 2D-CSI MR spectroscopy of the brain in the evaluation of patients with acute onset of neuropsychiatric systemic lupus erythematosus. Neuroradiology 2005, 47:576-585.
42. Handa R., Sahota P., Kumar M., Jagannathan N.R., Bal C.S., Gulati M., et al. In vivo proton magnetic resonance spectroscopy (MRS) and single photon emission computerized tomography (SPECT) in systemic lupus erythematosus (SLE). Magn Reson Imaging 2003, 21:1033-1037.
43. Lim M.K., Suh C.H., Kim H.J., Cho Y.K., Choi S.H., Kang J.H., et al. Systemic lupus erythematosus: brain MR imaging and single-voxel hydrogen 1 MR spectroscopy. Radiology 2000, 217:43-49.
44. Brooks W.M., Sibbitt W.L., Kornfeld M., Jung R.E., Bankhurst A.D., Roldan C.A. The histopathologic associates of neurometabolite abnormalities in fatal neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2010, 62:2055-2063.
45. Sabet A., Sibbitt W.L., Stidley C.A., Danska J., Brooks W.M. Neurometabolite markers of cerebral injury in the antiphospholipid antibody syndrome of systemic lupus erythematosus. Stroke 1998, 29:2254-2260.
46. Castellino G., Govoni M., Padovan M., Colamussi P., Borrelli M., Trotta F. Proton magnetic resonance spectroscopy may predict future brain lesions in SLE patients: a functional multi-imaging approach and follow up. Ann Rheum Dis 2005, 64:1022-1027.
47. Kao C.H., Ho Y.J., Lan J.L., Changlai S.P., Liao K.K., Chieng P.U. Discrepancy between regional cerebral blood flow and glucose metabolism of the brain in systemic lupus erythematosus patients with normal brain magnetic resonance imaging findings. Arthritis Rheum 1999, 42:61-68.
48. Chen J.J., Yen R.F., Kao A., Lin C.C., Lee C.C. Abnormal regional cerebral blood flow found by technetium-99m ethyl cysteinate dimer brain single photon emission computed tomography in systemic lupus erythematosus patients with normal brain MRI findings. Clin Rheumatol 2002, 21:516-519.
49. Huang W.S., Chiu P.Y., Tsai C.H., Kao A., Lee C.C. Objective evidence of abnormal regional cerebral blood flow in patients with systemic lupus erythematosus on Tc-99m ECD brain SPECT. Rheumatol Int 2002, 22:178-181.
50. Zhang X., Zhu Z., Zhang F., Shu H., Li F., Dong Y. Diagnostic value of single-photon-emission computed tomography in severe central nervous system involvement of systemic lupus erythematosus: a case-control study. Arthritis Rheum 2005, 53:845-849.
51. Lopez-Longo F.J., Carol N., Almoguera M.I., Olazaran J., Alonso-Farto J.C., Ortega A., et al. Cerebral hypoperfusion detected by SPECT in patients with systemic lupus erythematosus is related to clinical activity and cumulative tissue damage. Lupus 2003, 12:813-819.
52. Liu F.Y., Huang W.S., Kao C.H., Yen R.F., Wang J.J., Ho S.T. Usefulness of Tc-99m ECD brain SPECT to evaluate the effects of methylprednisolone pulse therapy in lupus erythematosus with brain involvement: a preliminary report. Rheumatol Int 2003, 23:182-185.
53. Okizaki A., Shuke N., Sato J., Maruyama N., Haneda M., Aburano T. Transient brain hyperperfusion detected with I-123 IMP SPECT in a patient with neuropsychiatric systemic lupus erythematosus. Clin Nucl Med 2009, 34:601-603.
54. Khubchandani R.P., Viswanathan V., Desai J. Unusual neurologic manifestations (I): Parkinsonism in juvenile SLE. Lupus 2007, 16:572-575.
55. Lee P.H., Joo U.S., Bang O.Y., Seo C.H. Basal ganglia hyperperfusion in a patient with systemic lupus erythematosus-related parkinsonism. Neurology 2004, 63:395-396.
56. Curiel R., Akin E.A., Beaulieu G., Depalma L., Hashefi M. PET/CT imaging in systemic lupus erythematosus. Ann N Y Acad Sci 2011, 1228:71-80.
57. Ramage A.E., Fox P.T., Brey R.L., Narayana S., Cykowski M.D., Naqibuddin M., et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum 2011, 63:3048-3057.
58. Fragoso-Loyo H., Cabiedes J., Atisha-Fregoso Y., Llorente L., Sanchez-Guerrero J. Utility of serum S100B protein for identification of central nervous system involvement in systemic lupus erythematosus. J Rheumatol 2010, 37:2280-2285.
59. Yang X.Y., Lin J., Lu X.Y., Zhao X.Y. Expression of S100B protein levels in serum and cerebrospinal fluid with different forms of neuropsychiatric systemic lupus erythematosus. Clin Rheumatol 2008, 27:353-357.
60. Zandman-Goddard G., Chapman J., Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 2007, 36:297-315.
61. Gono T., Kawaguchi Y., Kaneko H., Nishimura K., Hanaoka M., Kataoka S., et al. Anti-NR2A antibody as a predictor for neuropsychiatric systemic lupus erythematosus. Rheumatology (Oxford) 2011, 63:3952-3959.
62. Cohen-Solal J.F., Diamond B. Neuropsychiatric lupus and autoantibodies against ionotropic glutamate receptor (NMDAR). Rev Med Interne 2011, 32:130-132.
63. Baca V., Lavalle C., Garcia R., Catalan T., Sauceda J.M., Sanchez G., et al. Favorable response to intravenous methylprednisolone and cyclophosphamide in children with severe neuropsychiatric lupus. J Rheumatol 1999, 26:432-439.
64. Quintero-Del-Rio A.I., Van M. Neurologic symptoms in children with systemic lupus erythematosus. J Child Neurol 2000, 15:803-807.
65. Neuwelt C.M., Lacks S., Kaye B.R., Ellman J.B., Borenstein D.G. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995, 98:32-41.
66. Trevisani VF, Castro AA, Neves Neto JF, Atallah AN. Cyclophosphamide versus methylprednisolone for the treatment of neuropsychiatric involvement in systemic lupus erythematosus. Cochrane Database Syst Rev 2000:CD002265.
67. Ramos P.C., Mendez M.J., Ames P.R., Khamashta M.A., Hughes G.R. Pulse cyclophosphamide in the treatment of neuropsychiatric systemic lupus erythematosus. Clin Exp Rheumatol 1996, 14:295-299.
68. Boumpas D.T., Yamada H., Patronas N.J., Scott D., Klippel J.H., Balow J.E. Pulse cyclophosphamide for severe neuropsychiatric lupus. Q J Med 1991, 81:975-984.
69. Olfat M.O., Al-Mayouf S.M., Muzaffer M.A. Pattern of neuropsychiatric manifestations and outcome in juvenile systemic lupus erythematosus. Clin Rheumatol 2004, 23:395-399.
70. Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L., Jara L.J., Fraga-Mouret A., Miranda-Limon J.M., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005, 64:620-625.
71. Merrill J.T., Neuwelt C.M., Wallace D.J., Shanahan J.C., Latinis K.M., Oates J.C., et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010, 62:222-233.
72. Tokunaga M., Saito K., Kawabata D., Imura Y., Fujii T., Nakayamada S., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007, 66:470-475.
73. Tanaka Y., Yamamoto K., Takeuchi T., Nishimoto N., Miyasaka N., Sumida T., et al. A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007, 17:191-197.
74. Levy Y., Sherer Y., Ahmed A., Langevitz P., George J., Fabbrizzi F., et al. A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus 1999, 8:705-712.
75. Lim K.S., Cheong K.L., Tan C.T. Periodic lateralized epileptiform discharges in neuropsychiatric lupus: association with cerebritis in magnetic resonance imaging and resolution after intravenous immunoglobulin. Lupus 2010, 19:748-752.
76. Zandman-Goddard G., Levy Y., Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005, 29:219-228.
77. Kwong K.L., Chu R., Wong S.N. Parkinsonism as unusual neurological complication in childhood systemic lupus erythematosus. Lupus 2000, 9:474-477.
78. Sanna G., Bertolaccini M.L., Khamashta M.A. Neuropsychiatric involvement in systemic lupus erythematosus: current therapeutic approach. Curr Pharm Des 2008, 14:1261-1269.
79. Bartolucci P., Brechignac S., Cohen P., Le Guern V., Guillevin L. Adjunctive plasma exchanges to treat neuropsychiatric lupus: a retrospective study on 10 patients. Lupus 2007, 16:817-822.
80. Neuwelt C.M. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial 2003, 7:173-182.
81. Pagnoux C. Plasma exchange for systemic lupus erythematosus. Transfus Apher Sci 2007, 36:187-193.
82. Mok C.C. Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 2007, 36:329-337.